Temozolomide, a class 3.3 new antitumor drug of Hengrui medicine, has obtained clinical approval
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Temozolomide for injection of Hengrui medicine has completed the clinical examination and approval, and is in the state of pending certification It is worth noting that the temozolomide for injection is a class 3.3 new antitumor drug Hengrui medicine began to apply for clinical application in February 2011, and the clinical approval documents obtained in three years are expected to open a new market for the company Temozolomide, as a first-line drug for the treatment of malignant brain tumors, was first developed by Schering plough and listed in the European Union and the United States in 1998 and 1999 Among them, temozolomide for injection was approved by FDA on February 27, 2009 At present, only Jiangsu Tianshili Diyi Pharmaceutical Co., Ltd and Shuanglu Pharmaceutical Co., Ltd have been approved to produce the raw materials and capsules of the drug on the market Among them, Tianshili submitted the supplementary information of clinical application of temozolomide implant in August last year It is reported that temozolomide for injection has not been listed in China so far The new dosage form declared by Hengrui medicine is injection Some professionals pointed out that temozolomide intravenous injection will be more suitable for clinical use and improve the compliance of patients, so the research and development of temozolomide intravenous injection will have a good market prospect and value.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
